Nikolaos Naziris
Overview
Explore the profile of Nikolaos Naziris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kosti E, Sotiropoulou H, Tsichlis I, Tsakiri M, Naziris N, Demetzos C
Materials (Basel)
. 2024 Nov;
17(22).
PMID: 39597287
The aim of the present study is to evaluate the stability of DMPC:Pluronic F-127 and DPPC:Pluronic F-127 liposomes, both with and without incorporated quercetin. Quercetin belongs to the class of...
2.
Tsakiri M, Tabriz A, Naziris N, Rahali K, Douroumis D, Demetzos C
Int J Pharm
. 2024 Jan;
651:123788.
PMID: 38185341
Exosomes are naturally derived information carriers that present interest as drug delivery systems. However, their vague cargo and isolation difficulties hinder their use in clinical practice. To overcome these limitations,...
3.
Naziris N, Demetzos C
Adv Exp Med Biol
. 2023 Aug;
1425:575-589.
PMID: 37581831
Herein we present the modern issue of new health technologies that emerge in Medicine and Therapeutics, with regard to their development, regulatory framework, approval, and post-approval monitoring. The European law...
4.
Sekowski S, Naziris N, Chountoulesi M, Olchowik-Grabarek E, Czerkas K, Veiko A, et al.
J Funct Biomater
. 2023 Jun;
14(6).
PMID: 37367260
Tannins are natural plant origin polyphenols that are promising compounds for pharmacological applications due to their strong and different biological activities, including antibacterial activity. Our previous studies demonstrated that sumac...
5.
Michlewska S, Garaiova Z, Subjakova V, Holota M, Kubczak M, Grodzicka M, et al.
Colloids Surf B Biointerfaces
. 2023 May;
227:113371.
PMID: 37244201
One of the major limitations for the treatment of many diseases is an inability of drugs to cross the cell membrane barrier. Different kinds of carriers are being investigated to...
6.
Stampolaki M, Malwal S, Alvarez-Cabrera N, Gao Z, Moniruzzaman M, Babii S, et al.
ACS Infect Dis
. 2023 Jan;
9(2):342-364.
PMID: 36706233
SQ109 is a tuberculosis drug candidate that has high potency against and is thought to function at least in part by blocking cell wall biosynthesis by inhibiting the MmpL3 transporter....
7.
Naziris N, Sekowski S, Olchowik-Grabarek E, Buczkowski A, Balcerzak L, Chrysostomou V, et al.
Biomater Adv
. 2022 Nov;
144:213200.
PMID: 36442451
The technology of lipid nanoparticles has a long history in drug delivery, which begins with the discovery of liposomes by Alec D Bangham in the 1960s. Since then, numerous studies...
8.
Palli V, Leonis G, Zoupanou N, Georgiou N, Chountoulesi M, Naziris N, et al.
Molecules
. 2022 Apr;
27(8).
PMID: 35458617
Losartan potassium salt (LSR) is a well-known antihypertensive drug with proven beneficial effects on human health. Its formulation with the non-toxic 2-hydroxypropyl-β-cyclodextrin (2-HP-β-CD) could improve its pharmacological profile. Thus, its...
9.
Naziris N, Demetzos C
Adv Exp Med Biol
. 2022 Jan;
1339:385-394.
PMID: 35023130
Liposomes and lipidic vehicles are nanotechnological platforms that are present in the clinic and industry, with extensive application and much potential in the field of therapeutics. Currently, the obstacles associated...
10.
Naziris N, Demetzos C
Adv Exp Med Biol
. 2022 Jan;
1339:317.
PMID: 35023119
The fields of medicine and therapeutics have lately turned towards more modern approaches for the therapy of diseases. These approaches have been classified as new health technologies and various issues...